VIM and sarcoma: For comparative purposes, we also tested the detection of ASPS CTCs employing specific monoclonal antibodies against ASPL-TFE3 type 1 fusion protein [12] and vimentin (S7 Fig), as cell-surface vimentin (CSV) has been proposed as a marker of circulating sarcoma cells [13].